{"entity":{"id":"nct07472647","kind":"trial","name":"SYS6090 Combination Therapy in Advanced Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of pemetrexed, paclitaxel / nab-paclitaxel, docetaxel, bevacizumab and other drugs in lung cancer, run by Shanghai JMT-Bio Inc., not yet recruiting.","summary":"SYS6090 Combination Therapy in Advanced Lung Cancer is a phase 1/2, interventional study registered as NCT07472647 by Shanghai JMT-Bio Inc., with a registry enrolment figure of 596 participants, started 2026-02-28 and due to reach its primary completion in 2029-02-28. Interventions recorded: SYS6090 + pemetrexed + platinum-based chemotherapy; SYS6090 + paclitaxel + platinum-based chemotherapy; SYS6090 + docetaxel; SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapy; SYS6090 + SYS6010; SYS6090 + etoposide + platinum-based chemotherapy; SYS6090 + chemotherapy or other anticancer therapy. Conditions listed: Non-Small Cell Lung Cancer; Small Cell Lung Cancer. Primary outcome: Dose-Limiting Toxicity (DLT) (Phase Ib); Adverse Events (AEs) (Phase Ib); Objective response rate (ORR) (Phase II). Lung eligibility wording from the registry: \"Histologically or cytologically confirmed unresectable locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-small cell lung cancer (NSCLC) according to the AJCC/UICC Cancer Staging System, 8th edition, or extensive-stage small cell lung cancer (SCLC), not amenable to curative surgical res\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07472647","url":"https://clinicaltrials.gov/study/NCT07472647"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["sclc","nsclc"],"sections":[],"technologies":["antiangiogenic","cytotoxic-chemotherapy","monoclonal-antibody","topoisomerase-inhibitors"],"targets":[],"drugs":["pemetrexed","paclitaxel","docetaxel","bevacizumab","sys6010","etoposide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07472647","phase":"1/2","setting":"A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Efficacy of SYS6090 in Combination With Other Therapies in Participants With Advanced Lung Cancer","sponsor":"Shanghai JMT-Bio Inc.","enrolled":596,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07472647/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"sys6010","kind":"drug","name":"SYS6010","route":"/drugs/sys6010/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}